The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 17, 2023
Filed:
Aug. 25, 2020
Applicant:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Inventors:
Levi A. Garraway, Newton, MA (US);
Caroline Emery, Kansas City, MO (US);
Nikhil Wagle, Brookline, MA (US);
Assignee:
DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/00 (2006.01); A61K 39/00 (2006.01); G01N 33/574 (2006.01); C12N 9/12 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01); C12N 15/10 (2006.01); C12Q 1/6809 (2018.01); C12Q 1/6827 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
G01N 33/5743 (2013.01); A61K 38/005 (2013.01); A61P 35/00 (2018.01); C12N 9/1205 (2013.01); C12N 15/1003 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6809 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6886 (2013.01); C12Y 207/12002 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/91205 (2013.01); G01N 2500/10 (2013.01); G01N 2500/20 (2013.01);
Abstract
Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.